These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 39095563

  • 1. The impact of CLDN18.2 expression on effector cells mediating antibody-dependent cellular cytotoxicity in gastric cancer.
    Matsuishi A, Nakajima S, Saito M, Saito K, Fukai S, Tsumuraya H, Kanoda R, Kikuchi T, Nirei A, Kaneta A, Okayama H, Mimura K, Hanayama H, Sakamoto W, Momma T, Saze Z, Kono K.
    Sci Rep; 2024 Aug 02; 14(1):17916. PubMed ID: 39095563
    [Abstract] [Full Text] [Related]

  • 2. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer.
    Kubota Y, Kawazoe A, Mishima S, Nakamura Y, Kotani D, Kuboki Y, Bando H, Kojima T, Doi T, Yoshino T, Kuwata T, Shitara K.
    ESMO Open; 2023 Feb 02; 8(1):100762. PubMed ID: 36610262
    [Abstract] [Full Text] [Related]

  • 3. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer.
    Wang C, Wang Y, Chen J, Wang Y, Pang C, Liang C, Yuan L, Ma Y.
    BMC Gastroenterol; 2023 Aug 16; 23(1):283. PubMed ID: 37582713
    [Abstract] [Full Text] [Related]

  • 4. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma.
    Rohde C, Yamaguchi R, Mukhina S, Sahin U, Itoh K, Türeci Ö.
    Jpn J Clin Oncol; 2019 Sep 01; 49(9):870-876. PubMed ID: 31087075
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Tumor-Associated Monocytes/Macrophages Impair NK-Cell Function via TGFβ1 in Human Gastric Cancer.
    Peng LS, Zhang JY, Teng YS, Zhao YL, Wang TT, Mao FY, Lv YP, Cheng P, Li WH, Chen N, Duan M, Chen W, Guo G, Zou QM, Zhuang Y.
    Cancer Immunol Res; 2017 Mar 01; 5(3):248-256. PubMed ID: 28148545
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of anti-claudin 18.2 monoclonal antibody zolbetuximab alone or combined with chemotherapy or programmed cell death-1 blockade in syngeneic and xenograft gastric cancer models.
    Nishibata T, Weng J, Omori K, Sato Y, Nakazawa T, Suzuki T, Yamada T, Nakajo I, Kinugasa F, Türeci Ö, Şahin U, Yoshida T.
    J Pharmacol Sci; 2024 Jul 01; 155(3):84-93. PubMed ID: 38797537
    [Abstract] [Full Text] [Related]

  • 10. Analysis of the expression and genetic alteration of CLDN18 in gastric cancer.
    Li J, Zhang Y, Hu D, Gong T, Xu R, Gao J.
    Aging (Albany NY); 2020 Jul 15; 12(14):14271-14284. PubMed ID: 32668412
    [Abstract] [Full Text] [Related]

  • 11. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers.
    Zhong W, Lu Y, Ma Z, He Y, Ding Y, Yao G, Zhou Z, Dong J, Fang Y, Jiang W, Wang W, Huang Y.
    Front Immunol; 2022 Jul 15; 13():885424. PubMed ID: 35837391
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines.
    Gottschalk N, Lang S, Kimmig R, Singh M, Brandau S.
    BMC Cancer; 2012 Oct 04; 12():451. PubMed ID: 23036052
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Characterization of zolbetuximab in pancreatic cancer models.
    Türeci Ӧ, Mitnacht-Kraus R, Wöll S, Yamada T, Sahin U.
    Oncoimmunology; 2019 Oct 04; 8(1):e1523096. PubMed ID: 30546962
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
    Sahin U, Türeci Ö, Manikhas G, Lordick F, Rusyn A, Vynnychenko I, Dudov A, Bazin I, Bondarenko I, Melichar B, Dhaene K, Wiechen K, Huber C, Maurus D, Arozullah A, Park JW, Schuler M, Al-Batran SE.
    Ann Oncol; 2021 May 04; 32(5):609-619. PubMed ID: 33610734
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
    Park JE, Kim SE, Keam B, Park HR, Kim S, Kim M, Kim TM, Doh J, Kim DW, Heo DS.
    J Immunother Cancer; 2020 Aug 04; 8(2):. PubMed ID: 32830112
    [Abstract] [Full Text] [Related]

  • 20. Colitis-associated colorectal adenocarcinomas frequently express claudin 18 isoform 2: implications for claudin 18.2 monoclonal antibody therapy.
    Iwaya M, Hayashi H, Nakajima T, Matsuda K, Kinugawa Y, Tobe Y, Tateishi Y, Iwaya Y, Uehara T, Ota H.
    Histopathology; 2021 Aug 04; 79(2):227-237. PubMed ID: 33590909
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.